The innate immunity in alzheimer disease-relevance to pathogenesis and therapy

Current Pharmaceutical Design

Volumn 21, Issue 25, 2015, Pages 3582-3588

  Blach Olszewska, Zofia ^a   Zaczynska, Ewa ^a   Gustaw Rothenberg, Kasia ^b   Avila Rodrigues, Marco ^c   Barreto, George E ^c,d   Leszek, Jerzy ^e   Aliev, Gjumrakch ^f,g  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f GALLY International Biomedical Research Consulting LLC   (United States)

^g University of Atlanta   (United States)

Author keywords

Alzheimer disease; Human peripheral blood leukocytes; Innate immunity; Therapy

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; IMMUNOSUPPRESSIVE AGENT; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR; CHOLINESTERASE INHIBITOR; IMMUNOLOGIC FACTOR; INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNITY; EXTRACT; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RESISTANCE; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PRIORITY JOURNAL; STEROID THERAPY; VIRUS INFECTION; AGING; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MICROGLIA; OXIDATIVE STRESS;

AGING; ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINESTERASE INHIBITORS; DRUG DISCOVERY; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INTERFERONS; LEUKOCYTES; MICROGLIA; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940903691     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150710144829     Document Type: Article

References (102)

1. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014; 10: 217-24.
2. Doens D, Fernandez PL. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J Neuroinflammation 2014; 11: 48.
3. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation 2014; 11: 111.
4. Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014; 8: 112.
5. Sierra A, Abiega O, Shahraz A, Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 2013; 7: 6.
6. Van Nostrand WE, Davis J, Previti ML, Xu F. Clearance of amyloid- beta protein deposits in transgenic mice following focal cerebral ischemia. Neurodegener Dis 2012; 10: 108-11.
7. Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 2006; 24: 167-76.
8. Barreto GE, Santos-Galindo M, Garcia-Segura LM. Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury. Front Aging Neurosci 2014; 6: 132.
9. McGeer PL, McGeer EG. Autotoxicity and alzheimer disease. Arch Neurol 2000; 57: 789-90.
10. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 2009; 4: e7642.
11. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 2004; 101: 2173-8.
12. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005; 25: 9275-84.
13. Frank-Cannon TC, Tran T, Ruhn KA, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008; 28: 10825-34.
14. Godoy DA, Pinero GR, Svampa S, Papa F, Di Napoli M. Hyperglycemia and short-term outcome in patients with spontaneous intracerebral hemorrhage. Neurocrit Care 2008; 9: 217-29.
15. Nguyen TV, Stebbing MJ, Clerc N, Kawai M, Harvey JR, Furness JB. Evidence for protein kinase involvement in long-term postsynaptic excitation of intrinsic primary afferent neurons in the intestine. Auton Neurosci 2004; 115: 1-6.
16. Palin K, Moreau ML, Orcel H, et al. Age-impaired fluid homeostasis depends on the balance of IL-6/IGF-I in the rat supraoptic nuclei. Neurobiol Aging 2009; 30: 1677-92.
17. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 788-9.
18. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal antiinflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-69.
19. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009; 72: 1899-905.
20. Thal DR, Schultz C, Botez G, et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol 2005; 31: 270-9.
21. Group AR. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1: e33.
22. Lyketsos CG. Review: antidepressants improve depression in people with Alzheimer's disease. Evid Based Ment Health 2007; 10: 115.
23. Colton C, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010; 9: 174-91.
24. Blach-Olszewska Z, Zaczynska E, Kielbinski M, Frydecka I. Deficiency of innate immunity of leukocytes is associated with failure of the induction of remission and survival time in patients with acute leukemia. Pol J Environ Stud 2005; 14: 36-40.
25. Paradowska E, Blach-Olszewska Z, Gejdel E. Constitutive and induced cytokine production by human placenta and amniotic membrane at term. Placenta 1997; 18: 441-6.
26. Paradowska E, Blach-Olszewska Z, Sender J, Jarosz W. Antiviral nonspecific immunity of human placenta at term: possible role of endogenous tumor necrosis factors and interferons. J Interferon Cytokine Res 1996; 16: 941-8.
27. Zaczynska E, Blach-Olszewska Z, Gejdel E. Production of cytokines with antiviral activity by endothelial cells. J Interferon Cytokine Res 1995; 15: 811-4.
28. Zaczynska E, Blach-Olszewska Z, Sender J, Jarosz W. Effect of viral infections on the ability of human endothelium for interferon, tumor necrosis factor and interleukin 6 production. Arch Immunol Ther Exp (Warsz) 1997; 45: 243-7.
29. Orzechowska B, Antoszkow Z, Blach-Olszewska Z. Individual differentiation of innate antiviral immunity in humans; the role of endogenous interferons and tumor necrosis factor in the immunity of leukocytes. Arch Immunol Ther Exp (Warsz) 2003; 51: 51-60.
30. Orzechowska B, Blach-Olszewska Z. Acquisition of susceptibility to vesicular stomatitis virus infection by murine resident peritoneal cells during culturing in vitro. Arch Immunol Ther Exp (Warsz) 1996; 44: 325-8.
31. Zaczynska E, Olszewska ZB. Effect of cyclosporine A on the nonspecific, innate antiviral immunity of mice. Arch Immunol Ther Exp (Warsz) 2001; 49 Suppl 1: S53-57.
32. Orzechowska B, Antoszkow Z, Siemieniec I, Lorenc M, Jatczak B, Blach-Olszewska Z. Cytokine production by human leukocytes with different expressions of natural antiviral immunity and the effect of antibodies against interferons and TNF-alpha. Arch Immunol Ther Exp (Warsz) 2007; 55: 111-7.
33. Rosenthal KL, Zinkernagel RM, Hengartner H, et al. Persistence of vesicular stomatitis virus in cloned interleukin-2-dependent natural killer cell lines. J Virol 1986; 60: 539-47.
34. Coil DA, Miller AD. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 2004; 78: 10920-6.
35. Bloor S, Maelfait J, Krumbach R, Beyaert R, Randow F. Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus. Proc Natl Acad Sci USA 2010; 107: 6970-5.
36. Zaczynska E, Dus D, Paprocka M, Blach-Olszewska Z. Resistance of human leukocytes to vesicular stomatitis virus infection as one of the innate antiviral immune activities; participation of cell subpopulations. Folia Histochem Cytobiol 2008; 46: 39-43.
37. Mogensen SC. Genetics of macrophage-controlled resistance to hepatitis induced by herpes simplex virus type 2 in mice. Infect Immun 1977; 17: 268-73.
38. Scieux C. [Herpes simplex virus and macrophages]. Pathol Biol (Paris) 1997; 45: 159-64.
39. Bonina L, Iannello D, Merendino R, Arena A, Mastroeni P. Tumordependent resistance of rat peritoneal macrophages to herpes simplex virus. Infect Immun 1983; 39: 575-9.
40. Rybka K, Orzechowska B, Siemieniec I, et al. Age related natural antiviral non-specific immunity of human leukocytes. Med Sci Monit 2003; 9: BR413-7.
41. Jatczak B, Leszek J, Siemieniec I, et al. Age- and disease-related innate immunity of human leukocytes ex vivo. Exp Gerontol 2012; 47: 8-13.
42. Kong KF, Delroux K, Wang X, et al. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J Virol 2008; 82: 7613-23.
43. Saneto H, Kobayashi M, Kawamura Y, et al. Clinicopathological features, background liver disease, and survival analysis of HCVpositive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol 2008; 43: 975- 81.
44. Bali S, Kar SS, Kumar S, Ratho RK, Dhiman RK, Kumar R. Hepatitis E epidemic with bimodal peak in a town of north India. Indian J Public Health 2008; 52: 189-93, 199.
45. Saltykova TS. [Influenza morbidity and mortality from cardiovascular and respiratory diseases in elderly patients]. Ter Arkh 2008; 80: 40-44.
46. Blach-Olszewska Z. Innate immunity: cells, receptors, and signaling pathways. Arch Immunol Ther Exp (Warsz) 2005; 53: 245-53.
47. Piasecki E, Knysz B, Zwolinska K, et al. Inhibition of vesicular stomatitis virus replication in the course of HIV infection in patients with different stages of immunodeficiency. Viral Immunol 2010; 23: 567-76.
48. Sochocka M, Zaczynska E, Leszek J, Siemieniec I, Blach- Olszewska Z. Effect of donepezil on innate antiviral immunity of human leukocytes. J Neurol Sci 2008; 273: 75-80.
49. Sochocka M, Zaczynska E, Tabol A, Czarny A, Leszek J, Sobczynski M. The influence of donepezil and EGb 761 on the innate immunity of human leukocytes: effect on the NF-kappaB system. Int Immunopharmacol 2010; 10: 1505-13.
50. Blach-Olszewska Z, Jatczak B, Rak A, et al. Production of cytokines and stimulation of resistance to viral infection in human leukocytes by Scutellaria baicalensis flavones. J Interferon Cytokine Res 2008; 28: 571-81.
51. Gasiorowski K, Lamer-Zarawska E, Leszek J, et al. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration? CNS Neurol Disord Drug Targets 2011; 10: 184- 91.
52. Blach-Olszewska Z, Leszek J. Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. Neuropsychiatr Dis Treat 2007; 3: 365-72.
53. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak- Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.
54. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005; 204: 9-26.
55. Poea-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005; 174: 5941-9.
56. Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA, Group MS. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr 2005; 5: 2.
57. Nijhuis E, Hinloopen B, van Duijn C, Hofman A, Rozing J, Nagelkerken L. Decreased sensitivity to dexamethasone in lymphocytes from patients with Alzheimer's disease. Clin Immunol Immunopathol 1994; 73: 45-52.
58. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289: 2819-26.
59. Kukar T, Murphy MP, Eriksen JL, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005; 11: 545-50.
60. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 2010; 9: 132-9.
61. Luo W, Su YB, Hong C, et al. Design, synthesis and evaluation of novel 4-dimethylamine flavonoid derivatives as potential multifunctional anti-Alzheimer agents. Bioorg Med Chem 2013; 21: 7275-82.
62. Newman DJ, Cragg GM. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem 2004; 11: 1693-713.
63. Lv C, Wang L, Liu X, et al. Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model. Neuropharmacology 2015; 89: 175-84.
64. Silva T, Reis J, Teixeira J, Borges F. Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes. Ageing Res Rev 2014; 15: 116-45.
65. Lannfelt L, Relkin NR, Siemers ER. Amyloid-ss-directed immunotherapy for Alzheimer's disease. J Intern Med 2014; 275: 284-95.
66. Anekonda TS, Reddy PH. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev 2005; 50: 361-76.
67. Leszek J, Inglot AD, Janusz M, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 2002; 8: PI93-6.
68. Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz) 1999; 47: 377-85.
69. Kim HG, Moon M, Choi JG, et al. Donepezil inhibits the amyloidbeta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014; 40: 23-32.
70. Jiang Y, Zou Y, Chen S, et al. The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice. Neuropharmacology 2013; 73: 415-24.
71. Yoshiyama Y, Kojima A, Ishikawa C, Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010; 22: 295-306.
72. Tyagi E, Agrawal R, Nath C, Shukla R. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci 2007; 80: 1977-83.
73. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 2007; 6: 388-97.
74. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuroimmune- endocrine interactions: a role for the hypothalamicpituitary- adrenal revolving axis. J Neuroimmunol 2002; 133: 1-19.
75. Butt AM, Fern RF, Matute C. Neurotransmitter signaling in white matter. Glia 2014; 62: 1762-79.
76. Hosli E, Hosli L. Colocalization of neurotransmitter receptors on astrocytes in explant cultures of rat CNS. Neurochem Int 2000; 36: 301-11.
77. Hosli L, Hosli E, Kaser H. Colocalization of cholinergic, adrenergic and peptidergic receptors on astrocytes. Neuroreport 1993; 4: 679-82.
78. Tyagi E, Agrawal R, Nath C, Shukla R. Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation. Innate Immun 2010; 16: 3-13.
79. Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005; 40: 165-71.
80. Hwang J, Hwang H, Lee HW, Suk K. Microglia signaling as a target of donepezil. Neuropharmacology 2010; 58: 1122-9.
81. Leszek J, Basinski T, Kiejna A. Donepezil protects monocytes from Beta-amyloid - induced death. Neurobiol Aging 2004; 3: 281.
82. Mele T, Juric DM. Identification and pharmacological characterization of the histamine H3 receptor in cultured rat astrocytes. Eur J Pharmacol 2013; 720: 198-204.
83. Ferreira R, Santos T, Goncalves J, et al. Histamine modulates microglia function. J Neuroinflammation 2012; 9: 90.
84. Jung S, Pfeiffer F, Deitmer JW. Histamine-induced calcium entry in rat cerebellar astrocytes: evidence for capacitative and noncapacitative mechanisms. J Physiol 2000; 527 Pt 3: 549-61.
85. Katoh Y, Niimi M, Yamamoto Y, et al. Histamine production by cultured microglial cells of the mouse. Neurosci Lett 2001; 305: 181-4.
86. Teuscher C, Subramanian M, Noubade R, et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci USA 2007; 104: 10146-51.
87. Saxena G, Singh SP, Agrawal R, Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 2008; 581: 283-9.
88. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006; 149: 998-1012.
89. Barreto GE, Gonzalez J, Torres Y, Morales L. Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res 2011; 71: 107-13.
90. Cabezas R, Avila MF, Gonzalez J, El-Bacha RS, Barreto GE. PDGF-BB Protects Mitochondria from Rotenone in T98G Cells. Neurotox Res 2014; Dec 17 [Epub ahead of print].
91. Cabezas R, El-Bacha RS, Gonzalez J, Barreto GE. Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci Res 2012; 74: 80-90.
92. Tabet N. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing 2006; 35: 336-8.
93. Frank S, Copanaki E, Burbach GJ, Muller UC, Deller T. Differential regulation of toll-like receptor mRNAs in amyloid plaqueassociated brain tissue of aged APP23 transgenic mice. Neurosci Lett 2009; 453: 41-44.
94. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008; 5: 23.
95. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104: 13798-803.
96. Arroyo DS, Soria JA, Gaviglio EA, Rodriguez-Galan MC, Iribarren P. Toll-like receptors are key players in neurodegeneration. Int Immunopharmacol 2011; 11: 1415-21.
97. Dai XJ, Li N, Yu L, et al. Activation of BV2 microglia by lipopolysaccharide triggers an inflammatory reaction in PC12 cell apoptosis through a toll-like receptor 4-dependent pathway. Cell Stress Chaperones 2015; 20: 321-31.
98. Trotta T, Porro C, Calvello R, Panaro MA. Biological role of Tolllike receptor-4 in the brain. J Neuroimmunol 2014; 268: 1-12.
99. Salminen A, Suuronen T, Kaarniranta K. ROCK, PAK, and Toll of synapses in Alzheimer's disease. Biochem Biophys Res Commun 2008; 371: 587-90.
100. Liu S, Liu Y, Hao W, et al. TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 2012; 188: 1098-107.
101. Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators Inflamm 2010; pii: 497987.
102. MacDowell K, Caso J, Martin-Hernandez D, Madrigal J, Leza J, Garcia-Bueno B. Paliperidone prevents brain Toll-like receptor 4 pathway activation and neuroinflammation in rat models of acute and chronic restraint stress. Int J Neuropsychopharmacol 2014; 18: 3.